What is Genvor Inc's earnings per share (EPS)?

Genvor Inc (GNVR) reported diluted earnings per share of $-0.22 for fiscal year 2025. This represents a -46.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Genvor Inc Financials

GNVR

Source SEC Filings (10-K/10-Q) Updated Feb 12, 2026 Currency USD FYE September

This page shows Genvor Inc (GNVR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Genvor Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.10x

For every $1 of reported earnings, Genvor Inc generates $0.10 in operating cash flow (-$556K OCF vs -$5.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-107.2x

Genvor Inc earns $-107.2 in operating income for every $1 of interest expense (-$6.4M vs $60K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$6.4M

YoY-130.4%

Genvor Inc's EBITDA was -$6.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 130.4% from the prior year.

Net Income

-$5.6M

YoY-93.7%

Genvor Inc reported -$5.6M in net income in fiscal year 2025. This represents a decrease of 93.7% from the prior year.

EPS (Diluted)

$-0.22

YoY-46.7%

Genvor Inc earned $-0.22 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 46.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$37K

YoY+9881.5%

Genvor Inc held $37K in cash against $20K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

30M

YoY+48.9%

5Y CAGR+8.3%

Genvor Inc had 30M shares outstanding in fiscal year 2025. This represents an increase of 48.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$456K

YoY+89.8%

Genvor Inc invested $456K in research and development in fiscal year 2025. This represents an increase of 89.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

GNVR Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$456K+89.8%	$240K	$0	$0-100.0%	$226K	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	$24K+389.2%	$5K
Operating Income	-$6.4M-130.3%	-$2.8M-93.4%	-$1.4M	N/A	-$3.1M	N/A
Interest Expense	$60K+238.1%	$18K-59.6%	$44K	N/A	$103K	N/A
Income Tax	N/A	N/A	N/A	N/A	$0	N/A
Net Income	-$5.6M-93.7%	-$2.9M-69.0%	-$1.7M	N/A	-$3.4M-70526.8%	-$5K
EPS (Diluted)	$-0.22-46.7%	$-0.15-114.3%	$-0.07	N/A	$-0.15	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$57K0.0%	$57K	N/A	$272K+395.9%	$55K-13.6%	$63K	N/A	$44K
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	$563K+200.0%	-$563K	N/A	-$578K-109.2%	-$276K+94.5%	-$5.0M	N/A	-$572K
Interest Expense	$15K0.0%	$15K	N/A	$16K-29.6%	$23K+497.5%	$4K	N/A	$0
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$576K+200.0%	-$576K	N/A	-$398K-33.0%	-$299K+94.0%	-$5.0M	N/A	-$602K
EPS (Diluted)	$0.02+200.0%	$-0.02	N/A	$-0.010.0%	$-0.01+95.8%	$-0.24	N/A	$-0.03

GNVR Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$46K+28.8%	$36K-56.6%	$82K-74.0%	$316K-43.3%	$557K	$0
Current Assets	$46K+111.4%	$22K-67.3%	$66K-77.8%	$298K-44.3%	$536K	N/A
Cash & Equivalents	$37K+9881.5%	$373-99.2%	$44K-85.0%	$296K	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.4M-22.4%	$1.7M-2.1%	$1.8M+4.5%	$1.7M-33.7%	$2.6M+14768.2%	$17K
Current Liabilities	$1.4M-22.4%	$1.7M-2.1%	$1.8M+10.2%	$1.6M-33.8%	$2.4M+14023.2%	$17K
Long-Term Debt	$20K-97.8%	$905K-31.5%	$1.3M+15.6%	$1.1M	N/A	N/A
Total Equity	-$1.3M+23.4%	-$1.7M-0.5%	-$1.7M-22.3%	-$1.4M+31.0%	-$2.0M-11557.4%	-$17K
Retained Earnings	-$26.2M-27.1%	-$20.6M-16.3%	-$17.7M-10.5%	-$16.0M-35.9%	-$11.8M-28885.7%	-$41K

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$146K0.0%	$146K+218.1%	$46K-60.6%	$116K+453.3%	$21K-19.2%	$26K-26.8%	$36K+51.1%	$24K
Current Assets	$146K0.0%	$146K+218.1%	$46K-55.9%	$104K+1189.8%	$8K-36.1%	$13K-41.9%	$22K+135.8%	$9K
Cash & Equivalents	$104K0.0%	$104K+178.2%	$37K-62.4%	$99K+15334.2%	$641+10.3%	$581+55.8%	$373+164.5%	$141
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	-$914K-175.8%	$1.2M-11.3%	$1.4M-20.7%	$1.7M-18.3%	$2.1M+12.4%	$1.9M+6.7%	$1.7M+9.9%	$1.6M
Current Liabilities	$1.2M0.0%	$1.2M-11.3%	$1.4M-20.7%	$1.7M-18.3%	$2.1M+12.4%	$1.9M+6.7%	$1.7M+9.9%	$1.6M
Long-Term Debt	N/A	N/A	$20K	N/A	N/A	N/A	$905K	N/A
Total Equity	$1.1M+200.0%	-$1.1M+19.3%	-$1.3M+17.8%	-$1.6M+23.1%	-$2.1M-12.8%	-$1.8M-7.4%	-$1.7M-9.3%	-$1.6M
Retained Earnings	$26.8M+200.0%	-$26.8M-2.2%	-$26.2M+0.4%	-$26.3M-1.5%	-$25.9M-1.2%	-$25.6M-24.3%	-$20.6M-0.8%	-$20.4M

GNVR Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$556K+43.0%	-$976K-11.9%	-$872K	N/A	-$663K	$0
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	$0	$0
Financing Cash Flow	$593K-36.4%	$932K+50.3%	$620K	N/A	$900K	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$194K+200.0%	-$194K-24.3%	-$156K+52.4%	-$327K-360.2%	-$71K-4832.9%	-$1K+92.7%	-$20K+77.0%	-$86K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$260K0.0%	$260K+176.4%	$94K-77.9%	$426K+497.9%	$71K+4214.7%	$2K-91.8%	$20K-74.1%	$77K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GNVR Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-12197.3%-4088.9pp	-8108.4%-6027.7pp	-2080.7%	N/A	-617.6%	N/A
Current Ratio	0.03+0.0	0.01-0.0	0.04-0.1	0.18-0.0	0.22	N/A
Debt-to-Equity	-0.02+0.5	-0.53+0.2	-0.77+0.0	-0.82+0.5	-1.28-0.3	-1.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	54.4%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	395.4%+790.8pp	-395.4%	N/A	-341.7%+1079.3pp	-1421.0%+17778.5pp	-19199.4%	N/A	-2555.3%
Current Ratio	0.120.0	0.12+0.1	0.03-0.0	0.06+0.1	0.000.0	0.010.0	0.010.0	0.01
Debt-to-Equity	-0.86+0.3	-1.14-1.1	-0.02+1.1	-1.07-0.1	-1.010.0	-1.01-0.5	-0.53+0.5	-1.01
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Mustgrow Biologics Corp MGROF

$24.3M

Purebase PUBC

$6.7M

Co2 Gro BLONF

$1.4M

Sustainable Green Team Ltd SGTM

$46.7M

Itronics ITRO

$2.9M

Frequently Asked Questions

Is Genvor Inc profitable?

No, Genvor Inc (GNVR) reported a net income of -$5.6M in fiscal year 2025.

What is Genvor Inc's EBITDA?

Genvor Inc (GNVR) had EBITDA of -$6.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Genvor Inc have?

As of fiscal year 2025, Genvor Inc (GNVR) had $37K in cash and equivalents against $20K in long-term debt.

What is Genvor Inc's operating cash flow?

Genvor Inc (GNVR) generated -$556K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Genvor Inc's total assets?

Genvor Inc (GNVR) had $46K in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Genvor Inc spend on research and development?

Genvor Inc (GNVR) invested $456K in research and development during fiscal year 2025.

How many shares does Genvor Inc have outstanding?

Genvor Inc (GNVR) had 30M shares outstanding as of fiscal year 2025.

What is Genvor Inc's current ratio?

Genvor Inc (GNVR) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Genvor Inc's debt-to-equity ratio?

Genvor Inc (GNVR) had a debt-to-equity ratio of -0.02 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Genvor Inc's return on assets (ROA)?

Genvor Inc (GNVR) had a return on assets of -12197.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Genvor Inc's cash runway?

Based on fiscal year 2025 data, Genvor Inc (GNVR) had $37K in cash against an annual operating cash burn of $556K. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Genvor Inc's debt-to-equity ratio negative or unusual?

Genvor Inc (GNVR) has negative shareholder equity of -$1.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Genvor Inc's Piotroski F-Score?

Genvor Inc (GNVR) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Genvor Inc's earnings high quality?

Genvor Inc (GNVR) has an earnings quality ratio of 0.10x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Genvor Inc cover its interest payments?

Genvor Inc (GNVR) has an interest coverage ratio of -107.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.